The understanding of immune biology and the development of newer generations of immunotherapies have opened a new stage to ...
Celltrion announced on the 31st that it has signed a joint research and development agreement for a new immuno-oncology drug with MustBio, a domestic ...
Presentations to highlight ongoing clinical and translational research across PDS Biotechnology’s immunotherapy platforms ...
Company aims to shorten time frame to make PDS0101 available to patients with HPV16-positive head and neck cancer, projected to be the most ...
A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...
A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body’s ...
NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell DeathData Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- ...
Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...
A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's ...
Transgene and BioInvent are co-developing BT-001, an oncolytic virus developed using Transgene’s Invir.IO® platform armed to express GM-CSF and BioInvent’s full-length anti-CTLA-4 monoclonal antibody, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback